Staff profile

Dr Behzad Hajarizadeh

Research Fellow, Hepatitis Program

Faculty of Health Sciences

Australian Research Centre in Sex, Health and Society

 

Qualifications

Doctor of Medicine (MD), Masters of Public Health (MPH)

Area of study

Public Health

Brief profile

Dr Behzad Hajarizadeh is a Medical Practitioner and has a Masters in Public Health (MPH). His main area of expertise is viral hepatitis with more than ten years experience as a medical practitioner and researcher in the field of liver diseases. His employment history includes working as a senior research officer and project coordinator in the Iranian Ministry of Health and in the UNAIDS country office in Iran. He is currently working part-time on a few projects in the ARCSHS hepatitis program. These projects are ‘Connecting the Clinic to the Community: The Role of GPs and People with Chronic Hepatitis B’,  'Hepatitis B Patient and Clinical Practice Survey', 'The CHI Study' and ‘Chronic Hepatitis B and Culturally and Linguistically Diverse Communities’. He is particularly interested in the qualitative and quantitative studies in the field of viral hepatitis and HIV with a clinical or public health perspective. In terms of quantitative studies he has experience in statistical models, survival analysis, systematic review and meta-analysis and economical analysis.  

Research interests

Clinical Sciences

- Please contact me to discuss a topic.

Sexually Transmitted Infections

- Please contact me to discuss a topic.

Recent publications

  • Hajarizadeh B, Grebely J, Dore G. Case definitions for acute hepatitis C virus infection: A systematic review. Journal of Hepatology 2012 [in press]

  • Wallace J, McNally S, Richmond J, Hajarizadeh B, Pitts M. Challenges to the effective delivery of health care to people with chronic hepatitis B in Australia. Sexual Health. 2011;9(2):131-7

  • Wallace J, McNally S, Richmond J, Hajarizadeh B, Pitts M. Managing chronic hepatitis B: A qualitative study exploring the perspectives of people living with chronic hepatitis B in Australia. BMC Research Notes. 2011;4(45).

  • Alavian SM, Gooya MM, Hajarizadeh B (corresponding author), Esteghamati AR, Moeinzadeh AM, Haghazali M, et al. Mass vaccination campaign against hepatitis B in adolescents in Iran. Estimating coverage using administrative data. Hepatitis Monthly 2009;9(3):189-95. 

  • Movahedi M, Hajarizadeh B, Rahimi A, Arshinchi M, Amirhosseini K, Haghdoost AA. Trends and geographical inequalities of the main health indicators for rural Iran. Health Policy and Planning 2009;24:229-37. 

  • Alavian SM, Mohammad-Alizadeh AH, Esna-Ashari F, Ardalan G, Hajarizadeh B. Non-alcoholic fatty liver disease prevalence among school-aged children and adolescents in Iran and its association with biochemical and anthropometric measures. Liver International 2009;29(2):159-63. 

  • Tavallaii SA, Mirzamani M, Heshmatzade Behzadi A, Assari S, Khoddami Vishteh HR, Hajarizadeh B, Einollahi B. Sexual function: A comparison between male renal transplant recipients and hemodialysis patients. Journal of Sexual Medicine 2009;6(1):142-148. 

  • Sali S, Alavian SM, Hajarizadeh B (corresponding author). Effect of levamisole supplementation on hepatitis B virus vaccination response in hemodialysis patients. Nephrology 2008;13(5):376-9. 

  • Movahedi M, Haghdoost AA, Pournik O, Hajarizadeh B, Fallah MS. Temporal variations of health indicators in Iran comparing with other Eastern Mediterranean Region countries in the last two decades. Journal of Public Health 2008;30(4):499-504. 

  • Alavian SM, Hajarizadeh B, Ahmadzad-Asl M, Kabir A, Bagheri-Lankarani K. Hepatitis B virus infection in Iran: A systematic review. Hepatitis Monthly 2008;8(4):281-94. 

  • Haghdoost AA, Sadeghirad B, Hajarizadeh B, Mirzazadeh A. The application of systematic review and meta-analysis concepts in summarizing the findings of observational studies. Iranian Journal of Psychiatry 2007;2(4):132-136.

Older publications

  • Mirmomen S, Alavian SM, Hajarizadeh B, Kafaee J, Yektaparast B, Zahedi MJ, et al. Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infecions in patients with beta-thalassemia in Iran: a multicenter study. Archives of Iranian Medicine 2006;9(4):319-23.
  • Jahani MR, Alavian SM, Shirzad H, Kabir A, Hajarizadeh B. Distribution and risk factors of hepatitis B, hepatitis C, and HIV infection in a female population with "illegal social behaviour". Sexual Transmitted Infections 2005;81(2):185. 
  • Alavian SM, Hajarizadeh B, Nematizadeh F, Larijani B. Prevalence and determinants of diabetes mellitus among Iranian patients with chronic liver disease. BMC Endocrine Disorders. 2004;4(1):4. 
  • Alavian SM, Hajarizadeh B. Remarkable difference in the mode of HCV transmission among haemodialysis patients and IVDAs [letter]. Gut 2004;53(7):1057 
  • Alavian SM, Hajarizadeh B, Einollahi B. Efficacy and safety of Lamivudine on treatment of chronic hepatitis B in renal allograft recipients. Transplantation Proceedings 2003;35(7):2687-2688 
  • Alavian SM, Einollahi B, Hajarizadeh B, Bakhtiari S, Nafar M, Ahrabi S. Prevalence of hepatitis C virus infection and related risk factors among Iranian haemodialysis patients. Nephrology 2003;8(5):256-260 
  • Einollahi B, Hajarizadeh B, Bakhtiari S, Lesanpezeshki M, Khatami MR, Nourbala MH, et al. Pre-transplant hepatitis C virus infection and its effect on the post-transplant course of renal allograft recipients. Journal of Gastroenterology and Hepatology 2003;18(7):836-840